Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock
Portfolio Pulse from
ADMA Biologics, an infectious disease drug developer, demonstrates promising financial performance with significant earnings and revenue growth. The company has a Zacks Rank #2 (Buy), with expected quarterly earnings of $0.16 per share (100% increase year-over-year) and revenue estimates of $119.1 million (45.5% year-over-year growth). Despite a 'D' valuation grade, the stock has returned 22.2% over the past month.
March 21, 2025 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive earnings estimates, strong revenue growth, and consistent earnings surprises suggest potential short-term stock price appreciation.
Multiple positive indicators suggest potential stock price increase: 1) 100% earnings growth expectation, 2) 45.5% revenue growth, 3) Zacks Rank #2 (Buy), 4) Consistent earnings surprises in past quarters
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100